Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Esomeprazole - AstraZeneca

Next Previous
X
Search
Drug Profile

Esomeprazole - AstraZeneca

Alternative Names: D961H; Esomeprazole delayed-release capsules; Esomeprazole magnesium; Esoz; H-19918; H-19918 magnesium trihydrate; H199/18 magnesium trihydrate; Nexium; Nexium 24HR; Nexium Control; Nexium I.V.; Perprazole

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Daiichi Sankyo Company; Pfizer
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Anti-inflammatories; Antibacterials; Antiulcers; Gastric antisecretories; Small molecules
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bleeding ulcer; Duodenal ulcer; Gastric ulcer; Gastro-oesophageal reflux; Heartburn; Helicobacter infections; Jejunal ulcer; NSAID-induced ulcer; Peptic ulcer; Reflux oesophagitis; Zollinger-Ellison syndrome
  • Preregistration Stress ulcer
  • Phase III Erosive oesophagitis

Most Recent Events

  • 27 Dec 2022 AstraZeneca completes a phase III trial in Reflux oesophagitis, Gastric ulcer and Duodenal ulcer (Treatment-experienced, In children, In adolescents, In infants) in Japan (PO, Granules) (NCT03553563)
  • 09 Aug 2021 Phase-III clinical trials in Erosive oesophagitis (In children, Treatment-experienced) in Belgium (PO) (EudraCT2020-002515-21) .
  • 12 Mar 2021 AstraZeneca will market, distribute, and promote esomeprazole in Japan from September 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top